Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 8OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Down Syndrome 1

Interventions

Specimen Handling 16Magnetic Resonance Spectroscopy 13Vincristine 8Dexamethasone 8Radiation 7Cyclophosphamide 7Radiotherapy 6Leucovorin 6Lenalidomide 6Cisplatin 6daratumumab 5Radiotherapy, Conformal 5Radiosurgery 5Gemcitabine 5Doxorubicin 5Calcium Dobesilate 5dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4X-Rays 4Standard of Care 4Radiotherapy, Intensity-Modulated 4Practice Guidelines as Topic 4Paclitaxel 4Etoposide 4Cytarabine 4Bortezomib 4Biopsy 4pegaspargase 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × azathiopurine × 30 days × Clear all
NCT01190930 2026-05-28

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡